



L11 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:964186 HCAPLUS Full-text  
 DN 138:24959  
 TI Preparation of macrocycles useful in the treatment of Alzheimer's disease  
 IN Pulley, Shon R.; Beck, James P.; Tenbrink, Ruth E.; Jacobs, Jon S.  
 PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company  
 SO PCT Int. Appl., 173 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

|      | PATENT NO.       | KIND | DATE     | APPLICATION NO.  | DATE     |  |
|------|------------------|------|----------|--|----------|--|
| PI   | WO2002100399     | A1   | 20021219 | 2002WO-US18719   | 20020612 |  |
|      | W:               |      |          | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW |          |  |
|      | RW:              |      |          | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |  |
|      | CA---2450167     | A1   | 20021219 | 2002CA-2450167   | 20020612 |  |
|      | AU2002315098     | A1   | 20021223 | 2002AU-0315098   | 20020612 |  |
|      | EP---1395257     | A1   | 20040310 | 2002EP-0742038   | 20020612 |  |
|      | R:               |      |          | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR   |          |  |
|      | BR2002010391     | A    | 20040615 | 2002BR-0010391   | 20020612 |  |
|      | JP2005505506     | T    | 20050224 | 2003JP-0503220   | 20020612 |  |
|      | US2003236240     | A1   | 20031225 | 2002US-0170331   | 20020613 |  |
|      | US---7067507     | B2   | 20060627 |  |          |  |
|      | US2006003978     | A1   | 20060105 | 2005US-0208382   | 20050819 |  |
| PRAI | 2001US-297505P   | P    | 20010612 |  |          |  |
|      | 2001US-333082P   | P    | 20011119 |  |          |  |
|      | 2002WO-US18719   | W    | 20020612 |  |          |  |
|      | 2002US-0170331   | A3   | 20020613 |  |          |  |
| OS   | MARPAT 138:24959 |      |          |  |          |  |
| GI   |                  |      |          |  |          |  |



AB Macrocycles I [U is (un)substituted 1,3-dihydroxypropyl, 1-hydroxy-2-aminoethyl, oxiranyl, or 2-oxo-1,3-dioxolan-4-yl; V is (CH<sub>2</sub>)<sub>0-6</sub>; A, B, Y are (un)substituted

alkylene or alkenylene or rings of defined structure; D is CH<sub>2</sub>, CO, or SO<sub>2</sub>; X is absent, O, or an imino group; Z is absent, O, S, an imino group, CO, O<sub>2</sub>C, CO<sub>2</sub>, NHCO, or CONH] were prepared for treating Alzheimer's and similar diseases characterized by the deposition of A $\beta$  peptide in a mammal. Thus, macrocycle II was prepared by a multistep sequence involving reaction of 1-(allyloxy)-5-fluorobenzene with 2-(2,2-dimethyl[1,3]dioxolan-4-yl)aziridine-1-carboxylic acid tert-Bu ester.

IT 477954-35-1P 477954-37-3P 477954-39-5P  
 477954-41-9P 477954-43-1P 477954-44-2P  
 477954-46-4P 477954-48-6P 477954-52-2P  
 477954-55-5P 477954-56-6P 477954-57-7P  
 477954-58-8P 477954-60-2P 477954-61-3P  
 477954-62-4P 477954-64-6P 477954-66-8P  
 477954-68-0P 477954-69-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocycles useful in treatment of Alzheimer's disease)

RN 477954-35-1 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[3-ethylphenyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-37-3 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[1-(3-ethylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-39-5 HCAPLUS


CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[1-(3-ethynylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 477954-41-9 HCAPLUS  
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[(1R)-1-hydroxy-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]ethyl]-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 477954-43-1 HCAPLUS  
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[5-ethyl-3-pyridinyl]methyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 477954-44-2 HCAPLUS  
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[3-ethylphenyl]methyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-46-4 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[1-(3-ethylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-48-6 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-[(1R)-2-[[1-(3-ethynylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-52-2 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[(1R)-1-hydroxy-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]ethyl]-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-55-5 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[(5-ethyl-3-pyridinyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-56-6 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[(3-ethylphenyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-57-7 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[1-(3-ethylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-58-8 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[1-(3-ethynylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-60-2 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[(1R)-1-hydroxy-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]ethyl]-20-(2-oxazolyl)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 477954-61-3 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-


hexaene-2,17-dione, 4-[(1R)-2-[[[(5-ethyl-3-pyridinyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 477954-62-4 HCAPLUS  
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[(3-ethylphenyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 477954-64-6 HCAPLUS  
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[1-(3-ethylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 477954-66-8 HCAPLUS  
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[1-(3-ethynylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 477954-68-0 HCAPLUS  
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[(1R)-1-hydroxy-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]ethyl]-20-(2-oxazolyl)-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-69-1 HCAPLUS  
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[5-ethyl-3-pyridinyl]methyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





# RETABLE

| Referenced Author<br>(RAU) | Year<br>(RPY) | VOL<br>(RVL) | PG<br>(RPG) | Referenced Work<br>(RWK) | Referenced<br>File |
|----------------------------|---------------|--------------|-------------|--------------------------|--------------------|
| Fairlie, D                 | 1996          |              |             | WO-----9616950 A         | HCAPLUS            |
| Fairlie, D                 | 2000          | 7            | 1271        | JOURNAL OF MEDICINAL     |                    |